SCHEMBL9904552

SCHEMBL9904552

Cc1ccc(S(=O)(=O)n2cc(I)c3nc(-c4ccccc4F)ccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.42
ALDH3A1 P30838 2/20 0.42
NOD1 Q9Y239 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.40
UBE2N P61088 1/20 0.40
HTR6 P50406 2/20 0.40
PTGS2 P35354 2/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
PTGS1 P23219 1/20 0.36
TSHR P16473 1/20 0.36
KLK7 P49862 1/20 0.36
CYP19A1 P11511 1/20 0.36
RAPGEF4 Q8WZA2 1/20 0.36
CXCL8 P10145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904294 0.88 L3MBTL1 (0.40) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL9904606 0.80 L3MBTL1 (0.37) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL9904216 0.77 PIM1 (0.42) L3MBTL1HTR6
SCHEMBL31405764 0.77 L3MBTL1 (0.43) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL31617375 0.76 L3MBTL1 (0.42) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL12614891 0.74 KDM4E (0.39) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL12614982 0.74 L3MBTL1 (0.41) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL29414758 0.72 KDM4E (0.68) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL5429439 0.72 KDM4E (0.68) L3MBTL1ALDH3A1NOD1POLBHTT
SCHEMBL12615300 0.71 MEN1 (0.40) L3MBTL1ALDH3A1NOD1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 L3MBTL1 1581/4885ALDH3A1 1105/4885NOD1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.